Associated Papers
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Ojala VK et al.
Molecular Oncology, 2025
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer.
Siddiqui MT et al.
Molecular Oncology, 2025
Genetic analysis of ERBB4 gene in Chinese patients with amyotrophic lateral sclerosis: a single-center study and systematic review of published literature.
Shen D et al.
Frontiers in Aging Neuroscience, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma.
Dolgalev I et al.
Nature Communications, 2023
Neuroepithelial tumor with EWSR1::PATZ1 fusion: A literature review.
Kim H et al.
Journal of Neuropathology and Experimental Neurology, 2023
Genetic variability in sporadic amyotrophic lateral sclerosis.
Van Daele SH et al.
Brain : a Journal of Neurology, 2023
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
Rosenberg S et al.
Molecular Oncology, 2023
Somatic Mutation of PRKAR1A in Four Cases of Sporadic Cardiac Myxoma.
Sun Y et al.
Archives of Iranian Medicine, 2023
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM et al.
Pharmacological Reviews, 2022
Expanding the spectrum of EWSR1-PATZ1 rearranged CNS tumors: An infantile case with leptomeningeal dissemination.
Rossi S et al.
Brain Pathology (zurich, Switzerland), 2021
Ultradeep sequencing differentiates patterns of skin clonal mutations associated with sun-exposure status and skin cancer burden.
Wei L et al.
Science Advances, 2021
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lee B et al.
Frontiers in Oncology, 2021
Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors.
Feng Y et al.
Frontiers in Cell and Developmental Biology, 2021
Metastatic Syringocystadenocarcinoma Papilliferum: A Case Report, Tumor Genomic Profiling, and Literature Review.
Altunel E et al.
Case Reports in Oncological Medicine, 2020
High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer.
Lee SE et al.
Scientific Reports, 2019
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA et al.
Oncotarget, 2017
High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer.
Tan IB et al.
Genome Biology, 2015
ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C et al.
Methods in Molecular Biology (clifton, N.j.), 2014
The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
Zhou QM et al.
Chinese Journal of Cancer, 2013
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Dutton-Regester K et al.
Molecular Cancer Therapeutics, 2012
Analysis of the genome to personalize therapy for melanoma.
Davies MA et al.
Oncogene, 2010
A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U et al.
Cell Cycle (georgetown, Tex.), 2010